Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp

14 Oct 2024

Abstract excerpt

Tebentafusp, a bispecific immune therapy, is the only drug that demonstrated an overall survival benefit in patients with metastatic uveal melanoma (MUM). Circulating tumor DNA (ctDNA) has emerged as a potential prognostic and predictive marker in the phase 3 IMCgp100-202 trial using multiplex PCR-based next-generation sequencing (NGS). In this study (NCT02866149), ctDNA dynamics were assessed using droplet...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Immunotherapy and Immune Responses
Share to Ocular Oncology and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39402032
DOI: 10.1038/s41467-024-53145-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafuspPMID 39402032Read ↗

Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma.Semantic proximity Read ↗

Circulating tumor DNA monitoring in advanced mutated melanoma (LIQUID-MEL)Semantic proximity Read ↗

Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNASemantic proximity Read ↗

Dynamic ctDNA mutational complexity in melanoma patients receiving immunotherapySemantic proximity Read ↗

Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C InhibitionSemantic proximity Read ↗

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.Semantic proximity Read ↗

Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment.Semantic proximity Read ↗

Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.Semantic proximity Read ↗

In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibitionSemantic proximity Read ↗

Circulating Tumor DNA in Conjunctival Melanoma: Landscape and Surveillance Value.Semantic proximity Read ↗

Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy.Semantic proximity Read ↗

Development of a Nomogram to Predict Therapeutic Resistance in Metastatic Melanoma Using Longitudinal ctDNA Kinetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.